TC BioPharm is a UK company developing the field of cancer immunotherapy and aims to acquire approval for the manufacture and sale of ImmuniCell ™”, a cellular medicine using self-immunizing cells. The company has developed chimeric antigen receptor (CAR) modified gamma-delta T cells (GDT) and owns a unique technology with a demonstrable safety profile and established intellectual property rights for the entire GDT-based platforms. TCB and NIPRO will co-develop an autologous gamma-delta CAR-T therapy directed against CD19, which is expressed in several B cell tumors such as multiple myeloma and lymphoma. Preclinical studies developing the product will be supported by a Scottish Enterprise ‘seek-and-solve’ grant which will provide £2.7m of additional non-dilutive funding. TC BioPharm Co. has started a laboratory at the Life Innovation Center in Kawasaki, Kanagawa Prefecture.”

Nipro news release, February 7, 2018